Free tool
FAERS Monitor: Xarelto
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022406 or its brand name (Xarelto, Rivaroxaban). Reports on generic versions are filed under their own applications.
Reports
208,599
Serious
174,869
84% of reports
Hospitalization
104,161
Death reported
27,259
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- gastrointestinal haemorrhage21,673
- off label use8,056
- haemorrhage7,819
- dyspnoea7,421
- epistaxis6,806
- fatigue6,801
- death6,190
- fall6,184
- pulmonary embolism6,046
- drug ineffective6,005
- diarrhoea5,790
- anaemia5,772
- cerebrovascular accident5,648
- dizziness5,584
- nausea5,484
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 52 |
| 2010 | 55 |
| 2011 | 503 |
| 2012 | 3,861 |
| 2013 | 7,368 |
| 2014 | 9,409 |
| 2015 | 27,674 |
| 2016 | 29,714 |
| 2017 | 22,442 |
| 2018 | 21,010 |
| 2019 | 21,502 |
| 2020 | 14,671 |
| 2021 | 10,008 |
| 2022 | 10,492 |
| 2023 | 9,332 |
| 2024 | 8,319 |
| 2025 | 7,035 |
| 2026 | 5,145 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,845,560 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| gastrointestinal haemorrhageSignal | 21,673 | 34.9 | 34.4 | 531,471 |
| epistaxisSignal | 6,806 | 10.0 | 9.7 | 50,238 |
| haemorrhageSignal | 7,819 | 8.1 | 7.9 | 45,032 |
| pulmonary embolismSignal | 6,046 | 6.8 | 6.6 | 28,032 |
| cerebrovascular accidentSignal | 5,648 | 3.4 | 3.4 | 9,537 |
| anaemiaSignal | 5,772 | 3.1 | 3.0 | 8,112 |
| fall | 6,184 | 1.9 | 1.8 | 2,584 |
| dyspnoea | 7,421 | 1.3 | 1.3 | 603 |
| dizziness | 5,584 | 1.1 | 1.1 | 85 |
| off label use | 8,056 | 0.9 | 0.9 | 48 |
| diarrhoea | 5,790 | 0.9 | 0.9 | 61 |
| fatigue | 6,801 | 0.9 | 0.9 | 115 |
| death | 6,190 | 0.7 | 0.7 | 683 |
| nausea | 5,484 | 0.7 | 0.7 | 748 |
| drug ineffective | 6,005 | 0.5 | 0.4 | 4,115 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.